IQVIA Holdings Inc. (IQV)
Summary
IQV vs. PEN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Investors Should Hold IQV Stock in Their Portfolios Now
IQVIA's AI tools, record R&D backlog and strong free cash flow support its outlook, but weak liquidity and no dividend remain investor concerns.
IQVIA Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 29,713 | $5.98M | $6.21M | $226,210.7 | 3.78% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 136 | $29,650.08 | $28,425.36 | -$1,224.72 | -4.13% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 1,609 | $261,992.75 | $336,297.09 | $74,304.34 | 28.36% |
| CE Curtis Ellergodt Rothschild Investment LLC | 910 | $189,507.61 | $190,199.1 | $691.49 | 0.36% |
| SN Stephen Nickel CULLEN INVESTMENT GROUP Ltd. | 20,123 | $4.31M | $4.21M | -$108,496.88 | -2.51% |
IQVIA Holdings Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| EA Elizabeth Anderson Evercore ISI Group | 42.53 | $7,337.7 | $8,781.51 | $1,443.81 | 19.68% |
IQVIA Holdings Inc. (IQV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has IQVIA Holdings Inc. ever had a stock split?
IQVIA Holdings Inc. Profile
| Professional Services Industry | Industrials Sector | Ari Bousbib CEO | NYSE Exchange | 46266C105 CUSIP |
| US Country | 93,000 Employees | - Last Dividend | - Last Split | 9 May 2013 IPO Date |
Overview
IQVIA Holdings Inc. is a cutting-edge company providing a suite of analytics, technology solutions, and clinical research services tailored for the life sciences sector. Operating globally, including the Americas, Europe, Africa, and the Asia-Pacific regions, IQVIA stands at the forefront of facilitating healthcare advancements. The company is organized into three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, catering to a diverse range of needs within the pharmaceutical, biotechnology, medical device and diagnostic, and consumer health industries. Originally known as Quintiles IMS Holdings, Inc., it underwent a rebranding to IQVIA Holdings Inc. in November 2017. With its headquarters in Durham, North Carolina, IQVIA continues to foster collaborations, including a notable partnership with argenx SE, to drive innovation and improve patient outcomes in healthcare.
Products and Services
- Technology & Analytics Solutions
- Research & Development Solutions
- Contract Sales & Medical Solutions
This segment offers a plethora of cloud-based applications coupled with implementation services designed explicitly for life sciences and healthcare providers. It helps in generating real-world evidence for healthcare decision-making and enhancing patient outcomes. Among these services are strategic and implementation consulting, encompassing advanced analytics and commercial processes outsourcing. Moreover, IQVIA provides critical metrics related to pharmaceutical sales, prescribing trends, medical treatments, and various promotional activities, not to mention detailed sales or prescribing data at different geographical levels.
This division supports the full spectrum of clinical trial and research development, including project management, clinical monitoring, and patient-centric solutions. It assists in strategic planning and design for clinical trials, central laboratory services, genomic, bioanalytical, ADME (Absorption, Distribution, Metabolism, and Excretion), discovery, and vaccine and biomarker laboratory services, thereby accelerating the journey from early-stage research to market-ready products.
Focused on enhancing engagement with healthcare providers and patients, this segment delivers comprehensive services spanning from health care provider engagement to scientific strategy and medical affairs. These solutions aim to optimize interactions between the medical community and the industry to foster a deeper understanding and adoption of advanced healthcare solutions and treatments.
